newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors- DNase program progressing towards Phase 1 clinical